Quotient (NASDAQ:QTNT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports.

According to Zacks, “Quotient Limited is a commercial-stage transfusion diagnostics company. It is focused on supplying blood-grouping consumables and developing MosaiQ, a fully automated platform for use in donor centers and patient-testing sites. Quotient Limited is headquartered in Edinburgh, Scotland and Newton, Pennsylvania. “

Several other analysts have also weighed in on the company. BidaskClub raised Quotient from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Jefferies Financial Group raised their price objective on Quotient from $11.00 to $13.50 and gave the company a “buy” rating in a research note on Tuesday, March 5th. Finally, ValuEngine lowered Quotient from a “buy” rating to a “hold” rating in a research note on Friday, December 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $11.75.

Shares of QTNT traded down $0.02 during trading hours on Wednesday, hitting $8.96. 689 shares of the company were exchanged, compared to its average volume of 354,207. The firm has a market cap of $583.98 million, a P/E ratio of -4.46 and a beta of 1.32. Quotient has a fifty-two week low of $3.69 and a fifty-two week high of $11.15. The company has a debt-to-equity ratio of 4.95, a quick ratio of 6.05 and a current ratio of 6.87.

Quotient (NASDAQ:QTNT) last released its earnings results on Thursday, January 31st. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.01). The firm had revenue of $6.72 million during the quarter, compared to the consensus estimate of $6.20 million. On average, research analysts predict that Quotient will post -1.93 earnings per share for the current fiscal year.

Institutional investors have recently bought and sold shares of the business. SlateStone Wealth LLC bought a new position in Quotient in the fourth quarter valued at about $91,000. Trexquant Investment LP raised its position in shares of Quotient by 102.5% during the third quarter. Trexquant Investment LP now owns 25,819 shares of the company’s stock worth $195,000 after acquiring an additional 13,070 shares during the last quarter. PEAK6 Investments LLC raised its position in shares of Quotient by 398.7% during the fourth quarter. PEAK6 Investments LLC now owns 71,769 shares of the company’s stock worth $439,000 after acquiring an additional 57,379 shares during the last quarter. Castleark Management LLC bought a new position in shares of Quotient during the fourth quarter worth about $462,000. Finally, Victory Capital Management Inc. bought a new position in shares of Quotient during the fourth quarter worth about $1,224,000. Hedge funds and other institutional investors own 66.27% of the company’s stock.

About Quotient

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.

Further Reading: Net Income

Get a free copy of the Zacks research report on Quotient (QTNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.